What Role Do Essential Genes Play in Cancer Immunotherapy Success?Specialty Pharmacy TimesImmunotherapy relies on T cells to attack and destroy tumors. Although this approach continues to show promise in the oncology space, some patients are unresponsi… Continue reading
OncLiveSpeculation Mounts About Price Tag for Emerging CAR TherapiesOncLiveChimeric antigen receptor (CAR) T-cell therapies could spawn a new and lucrative industry in anticancer immunotherapy, resulting in single-infusion treatments costing hundreds o… Continue reading
AGDAILY |
Monsanto gains access to ToolGen CRISPR platform | AGDAILY
AGDAILY Monsanto and ToolGen, have reached a global licensing agreement for the use of ToolGen’s CRISPR technology platform to develop agricultural products. Monsanto (MON) Signs Deal with ToolGen for CRISPR TechnologyNasdaq |
Forbes |
Discovery’s ‘First In Human’ Calls Much-Needed Attention To Clinical Trials
Forbes Cooper enrolled in a trial of a chimeric antigen receptor T cell (CAR-T) therapy, which involved removing T cells from his blood and engineering them to recognize and attack his cancer. This technology that has been in the spotlight lately, thanks to … |
Telegraph.co.uk |
Gene therapy darling Oxford BioMedica pares losses
Telegraph.co.uk A darling British biotech that is working on the development of the world’s leading gene therapy for cancer has posted reduced losses and a leap in sales. Oxford BioMedica signed a deal worth up to $100m (£77m) with Swiss drugs giant Novartis last … |
NormanObserver.com |
Abeona Therapeutics to Host Gene Therapy R&D Day on October 11, 2017
Nasdaq NEW YORK and CLEVELAND, Aug. 17, 2017 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, today … Abeona Therapeutics Announces Pivotal Expansion Of Gene Therapy Trials In Sanfilippo Syndrome Type AClinical Leader Abeona Therapeutics Inc. (ABEO) Releases Quarterly Earnings Results, Misses Expectations By $0.07 EPSStock Observer What Next for Abeona Therapeutics Inc (ABEO) Stock After Today’s …Press Telegraph Bloomberg all 36 news articles » |
|
Can Pfizer Bank on New Immunotherapy Bavencio for Growth?
Zacks.com As demand for immuno-oncology drugs and their combinations rises, Pfizer, Inc.’s (PFE – Free Report) newly approved immunotherapy, Bavencio, is being considered a significant top-line driver for this New York-based pharma giant. Pfizer’s shares are up … |